SARM
GLPG-0492
SaveA non-steroidal SARM developed by Galapagos NV for muscle wasting and sarcopenia, with Phase I data in healthy volunteers.
Quick verdict
One of the few SARMs with published Phase I human data. Development appears paused; no Phase II efficacy results are public.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Phase I trial in healthy males showed dose-proportional pharmacokinetics and acceptable tolerability. Preclinical models demonstrated partial reversal of muscle atrophy. No efficacy trial results published.
Benefits
- Phase I human tolerability data available
- Preclinical anti-atrophy effects in disuse models
Dosage notes
Phase I explored doses up to 12 mg/day. No therapeutic dose established.
Side effects
- Mild headache in Phase I
- Potential hormonal suppression
Who should be cautious
Not approved for clinical use. Only short-duration human safety data available.
What this page cannot tell you
Phase I results address safety and pharmacokinetics, not clinical efficacy.
Leaderboard scores
- Muscle35
- Recovery25
Write a review
Sign in to write a review.